Bimatoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes. It binds to the prostanoid FP receptor.
For the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.
Bimatoprost ophthalmic (for the eyes) is used to treat certain types of glaucoma and other causes of high pressure inside the eye. Bimatoprost ophthalmic may also be used for purposes not listed in this medication guide.
Bimatoprost is a prostamide, a synthetic structural analog of prostaglandin with ocular hypotensive activity, that is chemically related to prostamide F. It selectively mimics the effects of naturally occurring substances, prostamides.
Bimatoprost lowers intraocular pressure (IOP) in humans. Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes.
Bimatoprost reduces the pressure in the eye by mimicking the action of a naturally-occuring prostaglandin. Prostaglandins are a group of chemicals found in many places in the body. In the eye, they increase the drainage of the aqueous humour out of the eyeball.
Bimatoprost is a synthetic compound related to one of the natural prostaglandins, and works by increasing the drainage of aqueous humour out of the eyeball. Bimatoprost may also lower the rate of aqueous formation in the eye. Both these effects decrease the pressure within the eye.
Metabolism: Bimatoprost undergoes oxidation, N-deethylation and glucuronidation to form a variety of metabolites.
Absorption: Systemically absorbed when administered to the eye.
Route of elimination: Up to 67% of the administered dose was excreted in the urine while 25% of the dose was recovered in the feces.
Half life: Elimination half-life is approximately 45 minutes.
All medicines may cause side effects, but many people have no, or minor, side effects.Some medical conditions may interact with Bimatoprost.
Tell your doctor or pharmacist if you have any medical conditions.
Common side effects may include: eye redness.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider.
